KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Sales (2016 - 2025)

Inovio Pharmaceuticals' Return on Sales history spans 16 years, with the latest figure at 476.54% for Q3 2025.

  • For Q3 2025, Return on Sales rose 8043.0% year-over-year to 476.54%; the TTM value through Sep 2025 reached 476.54%, up 8043.0%, while the annual FY2024 figure was 495.09%, 33270.0% down from the prior year.
  • Return on Sales for Q3 2025 was 476.54% at Inovio Pharmaceuticals, up from 507.16% in the prior quarter.
  • Across five years, Return on Sales topped out at 4.13% in Q3 2022 and bottomed at 556.98% in Q3 2024.
  • The 5-year median for Return on Sales is 243.58% (2023), against an average of 271.39%.
  • The largest annual shift saw Return on Sales surged 20214bps in 2022 before it plummeted -46963bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 127.45% in 2021, then tumbled by -243bps to 436.87% in 2022, then skyrocketed by 44bps to 243.58% in 2023, then soared by 32bps to 166.82% in 2024, then crashed by -186bps to 476.54% in 2025.
  • Per Business Quant, the three most recent readings for INO's Return on Sales are 476.54% (Q3 2025), 507.16% (Q2 2025), and 371.0% (Q1 2025).